SURVYR

GH

Guardant Health, Inc.
$182.59
+$4.53 (2.54%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-7%+37%+81%+125%+170%Oct 2025Oct 2026Apr 202652w high $191.0552w low $66.59
GHSPY
Wall St. Highest PT $240.00 (+31.4%) Wall St. Avg PT $201.64 (+10.4%)
$70$114$158$203$247POC $99Hi $240Avg $202
Underwater Drawdown %Max DD -33.0%Current -2.5%
0.0%-33.0%
Relative Strength vs SPY+143.8% vs SPYOutperforming
+172%0%-172%
1W
+$15.93 (9.56%)
1M
+$5.26 (2.97%)
3M
+$38.52 (26.74%)
6M
+$99.18 (118.91%)
YTD
+$80.45 (78.76%)
1Y
+$113.01 (162.42%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
25 analysts · mean score 1.31
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$182.59
Average target$201.64
+$19.05 (+10.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$105.00
Median$201.64
High$240.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-13 · Morgan Stanley reiterated Overweight on GH
Reiterated
2026-10-07 · Barclays reiterated Overweight on GH
Reiterated
2026-10-01 · Guggenheim reiterated Buy on GH
Reiterated
2026-09-09 · UBS reiterated Buy on GH
Initiated
2026-09-08 · Rothschild & Co started covering GH at Buy
Reiterated
2026-09-02 · BTIG reiterated Buy on GH
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$22.4B
P/E (next 12 months, estimated)-407.8
52-week range$66.59 – $191.05
Revenue growth (latest quarter vs a year ago)+44.3%
Dividend yieldNo dividend
Analyst consensusStrong Buy (25)
Average analyst price target$201.64 (+10%)

What they do

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling. It also provides Shield blood test for colorectal cancer screening in adults.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for GH yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

GH earningsNext report in 7 days
Next report · quarter Sep 2026
Thu Nov 5, 2026After the close
EPS consensus-$0.32 range -$0.39–-$0.22
Revenue consensus$350.7M 21 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026-$0.42est -$0.39−7.8%Below estimates
May 7, 2026-$0.45est -$0.47+5.0%Above estimates
Feb 19, 2026-$0.50est -$0.47−6.5%Below estimates
Oct 29, 2025-$0.39est -$0.49+20.3%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 18:14:10 ET
24-1125-0225-0425-0725-1026-0226-0526-07-0.620.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$335.0M+44.3%
2026-03-31$301.7M–
2025-12-31$281.3M–
2025-09-30$265.2M–
2025-06-30$232.1M–

News & catalysts

More news
Top Specialty Lab Stocks to Watch This Earnings Season, According to BTIG
Investing.com · 1h ago
Can You Still Buy Tempus AI Stock Today?
Trefis · 21h ago
What Happens To Tempus AI Stock If Its Cash Burn Continues?
Trefis · Oct 26
Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More
24/7 Wall St. · Oct 23
IBD Stock Of The Day, Natera, Hovering Near Buy Point
Investor's Business Daily · Oct 22
Rating changes
Reiterated
2026-10-13 · Morgan Stanley reiterated Overweight on GH
Reiterated
2026-10-07 · Barclays reiterated Overweight on GH
Reiterated
2026-10-01 · Guggenheim reiterated Buy on GH
Reiterated
2026-09-09 · UBS reiterated Buy on GH
Initiated
2026-09-08 · Rothschild & Co started covering GH at Buy
Reiterated
2026-09-02 · BTIG reiterated Buy on GH

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Tariq Musa
Director · 2026-10-16
Sell
$19.2K
Azar Alex M Ii
Director · 2026-10-14
Sell
$11.0K
Tariq Musa
Director · 2026-09-16
Sell
$20.3K
Azar Alex M Ii
Director · 2026-09-16
Sell
$144.6K
Krognes Steve E.
Director · 2026-09-16
Sell
$172.3K
Krognes Steve E.
Director · 2026-09-16
Sell
$229.2K
Krognes Steve E.
Director · 2026-09-16
Sell
$578.9K
Krognes Steve E.
Director · 2026-09-16
Sell
$192.4K
Chudova Darya
Chief Technology Officer · 2026-09-15
Sell
$1.4M
Kalia Kumud
Chief Information Officer · 2026-09-11
Sell
$632.2K
Talasaz Amirali
Director, Co-Chief Executive Officer · 2026-08-21
Sell
$1.3M
Talasaz Amirali
Director, Co-Chief Executive Officer · 2026-08-21
Sell
$3.5M

Stats refreshed 2026-10-21 18:14:10 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026